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AbstrAct
background: Brachytherapy for carcinoma cervix has moved from point a based planning to optimization of dose based on 
hr-cTV. Guidelines have been published by Gec esTrO on hr-cTV delineation based on clinical gynecological examination 
and Mr sequences. These have given significant clinical results in terms of local control. however, many centers around the 
country and worldwide still use cT based planning, which restricts hr-cTV delineation, as disease and cervix can rarely be 
differentiated on a planning cT. Various studies have been done to develop cT based contouring guidelines from the available 
data, but enough evidence is not available on the clinical outcome when treatment is optimized to hr-cTV contoured on cT 
images. The purpose of this study is to find out the relation between local control and dosimetry of hr-cTV as delineated on 
cT images.
Materials and methods: patients of locally advanced carcinoma cervix treated radically with eBrT of 50 Gy in 25# and at least 
4 cycles of concurrent weekly cisplatin having a complete or partial response to eBrT were taken for study. all patients had 
completed cT based Intracavitary brachytherapy to 21 Gy in 3# of 7 Gy per # with dose prescription at point a and optimiz-
ing dose to reduce bladder and rectal toxicity. Follow up data on locoregional recurrence was obtained. hr-cTV delineation 
was done retrospectively on the treatment plan following guidelines by Viswanathan et al. eQD2 doses for eBrT+BT were 
calculated for point a and hr-cTV D90. The dosimetric data to hr-cTV and to point a were then compared with patients with 
locoregional control and with local recurrence. 
results: 48 patients were taken, all had squamous cell carcinoma. The median age was 48 years. 33.33% were stage IIa, the 
rest were stage IIB. Median follow-up was 30 months with 25% developing recurrence of the disease. hr-cTV D90 eQD2 dose 
was significantly higher in patients with locoregionally controlled disease than in patients with local recurrence (83.97 Gy10 
vs. 77.96 Gy10, p = 0.002). patients with hr-cTV D90 eQD2 dose greater than or equal to 79.75 Gy 10 had better locoregional 
control than patients receiving dose less than 79.75 Gy10 (p = 0.015). Kaplan Meier plot for pFs showed significantly improved 
pFs for patients receiving hr-cTV D90 dose of at least 79.75 Gy10 (log-rank p-value = 0.007). Three year progression free sur-
vival was 87.1% in patients receiving hr-cTV D90 dose of at least 79.75 Gy10.
conclusion: cT based hr -cTV volume delineation with the help of pre brachytherapy clinical diagrams and MrI imaging may 
be feasible in a select subgroup of patients with complete or near-complete response to external beam radiation. 
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Introduction
Carcinoma cervix is one of the major contribu-
tors to the cancer burden in developing countries 
like India. The widespread risk factors favor the 
high incidence of the disease in the rural parts 
of the nation. The government had taken utmost 
measures to implement screening programs like 
Lugol’s iodine screening, Pap smear examination, 
and health education programs with a prime idea 
to aid early diagnosis and prompt treatment [1]. 
Although screening programs are available, they 
remain highly unutilized leading to a large number 
of patients presenting at a locally advanced stage at 
the first point of contact with healthcare. With the 
majority presenting at a locally advanced stage of 
the disease, radiation therapy becomes the primary 
treatment modality in our country. 
The basic treatment of locally advanced carcino-
ma of the cervix is external beam radiotherapy with 
concurrent chemotherapy followed by brachyther-
apy, radical surgery being preserved for selected 
cases only [2, 3]. Brachytherapy forms the most in-
tegral part of carcinoma cervix radiotherapy aiding 
to deliver a very high local dose to the region. For 
many years, the dose was prescribed to Point A as 
described by Todd and Meredith and dose report-
ing was done based on the International Commis-
sion of Radiation Units and Measurements (ICRU) 
38 protocol [4], with orthogonal radiographs as im-
aging. However, high dose rate (HDR) brachythera-
py requiring multiple applications, slight variations 
in the application geometry led to a change in posi-
tions of point A and dose reporting points resulting 
in reporting variations [5, 6]. Another drawback 
was that the original definition being based solely 
on anatomical landmarks was not identified on 
a radiograph. Point-based prescription also did not 
correlate well with local control [7].
With the introduction of modern imaging devic-
es like Computed Tomography (CT) scan and Mag-
netic Resonance Imaging (MRI), dose prescription 
to the actual Clinical Target Volume (CTV) and 
dose reporting to target and Organ at Risk (OAR) 
made more sense than arbitrary points [8]. Most 
recent guidelines recommend MRI based Image 
Guided Adaptive Brachytherapy for Carcinoma 
[9–14]. Evidence from RetroEMBRACE and EM-
BRACE I studies have shown improvement in sur-
vival which also paved the way for dose prescription 
to High Risk Clinical Target Volume (HR-CTV) 
from conventional point A [15, 16]. However, 
recommendations for HR-CTV and intermediate 
risk clinical target volume (IR-CTV) delineation 
are provided by guidelines I–IV by Gynaecology 
Groupe Européen de Curiethérapie and the Euro-
pean SocieTy for Radiotherapy & Oncology ( Gyn 
GEC ESTRO) which is applicable only for MRI 
based applications [10, 11, 13, 14]. Although con-
sidered the gold standard, limitations to the use of 
MRI based brachytherapy is the availability of ad-
vanced MRI simulator, MRI compatible applicators, 
and some degree of institutional experience.
Such standards cannot be maintained in re-
source-constrained high volume institutions in our 
country which only have CT simulators. Certain 
drawbacks of CT based target delineation are the 
inability to identify the Gross Tumour Volume 
(GTV) from normal cervical tissue, and difficulty to 
identify the upper border of the cervix [17]. Various 
attempts at HR-CTV delineation based on CT scan 
have been made, with the study by Viswanathan et 
al. [17–19] being the most standardized of them. 
This study has provided contouring guidelines and 
atlas for standardized CT based HR-CTV delinea-
tion based on Gyn GEC ESTRO MRI recommen-
dations, although, data on clinical outcome of such 
recommendations are inadequate. A part of the 
sample of the RetroEMBRACE study had patients 
who had been treated following Viswanathan et al. 
guidelines, however, the clinical outcome from that 
subgroup was not separately reported in the [15].
Our objective is to determine whether dose to 
HR-CTV delineated on a CT scan based on avail-
able guidelines correlate with adequate local control 
in locally advanced carcinoma cervix treated with 
intracavitary brachytherapy.
Materials and methods
Computer tomography based intracavitary 
brachytherapy was started in Medical College Hos-
pital, Kolkata, around 2006; however, for over a de-
cade target delineation was not routinely done. Only 
around and after 2013, CT based HR-CTV contour-
ing was started in selected cases, however, dose pre-
scription and planning was still point-based. We have 
retrospectively selected a cohort of patients receiving 
intracavitary HDR brachytherapy during the period 
from January 2015 till December 2015 for this study.
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patient selection
The inclusion criteria were biopsy proven cas-
es of locally advanced carcinoma cervix who had 
completed external beam radiotherapy with a total 
dose of 50 Gy in 25 fractions in 5 weeks with at least 
4 cycles of concurrent Cisplatin chemotherapy, had 
a complete or partial response to external beam ra-
diotherapy (EBRT) as validated by post-EBRT clini-
cal examination and/or by MRI, and received CT 
based intracavitary brachytherapy with 3 fractions 
of 7 Gy per fraction with dose prescription to point 
A as per our institutional protocol. Other inclusion 
criteria were Performance Status of 0 or 1 before 
starting brachytherapy, normal blood and bio-
chemistry profile, and treatment completion within 
9 weeks. Presence of any degree of uterine prolapse, 
past pelvic surgery apart from biopsy, intracavitary 
applications other than standard tandem ovoid or 
tandem ring, and EBRT dose other than 50 Gy, 
altered fractionation were excluded from the study. 
The presence of a retroverted uterus or an imperfect 
application also led to the exclusion from the study. 
During the study period selected, a total of 245 
patients of cervical cancers were treated at our de-
partment, among whom 72 cases received postop-
erative radiotherapy and the remaining 173 were 
treated radically with radiotherapy. Among these, 
51 needed interstitial application or combination 
of intracavitary and interstitial application due to 
residual parametrial disease or less than near com-
plete response to EBRT, which could not be cov-
ered with a standard intracavitary technique. The 
remaining 122 patients were screened and only 48 
deemed suitable for the study as per the inclusion 
and exclusion criteria.
external beam radiotherapy
All patients in the study had completed EBRT to 
the whole pelvis to a total dose of 50 Gy in 25 frac-
tions over 5 weeks with concurrent weekly Cispla-
tin 40 mg/m2 body surface area (BSA). The EBRT 
machine was a Theratron 780C (Best Theratronics, 
Canada) Cobalt 60 unit. The treatment was done 
using a conventional 4 field box technique. The 
stringent EBRT inclusion criteria were to ensure 
that the limitations of the EBRT technique and re-
porting had less control on the outcome in terms 
of local control and the local control thus assessed 
can be attributed more to the dosimetry of brachy-
therapy.
Brachytherapy
Brachytherapy was delivered using an Iridium 
192 remote after loader (GammaMed plus, Varian 
Medical Systems, Palo Alto, California) based on 
our Institutional Protocol of 3 fractions of 7 Gy per 
fraction weekly. Two types of CT compatible appli-
cators, namely Fletcher and Ring applicators, were 
used for Intracavitary brachytherapy (ICBT) appli-
cation. The applicators consisted of uterine tandem 
with various angles (15°, 30°, 45°). Before each ap-
plication, a urinary catheter was inserted and the 
catheter balloon was inflated with contrast media (7 
mL) to localize the bladder neck. Patients followed 
specific instructions for rectal preparation before 
the ICBT procedure which included the taking of 
bisacodyl tablets (20 mg) the previous night and use 
of sodium phosphates enema early in the morning 
on the day of the procedure. Appropriate anterior 
and posterior vaginal packing was used to fix the 
applicator position and to displace the bladder and 
rectum away from the vaginal applicators. After the 
intracavitary application, the applicator was fixed 
with the help of roller gauze bandages. 
All patients underwent a CT scan followed by 
treatment planning during the first and third frac-
tion of brachytherapy application, the treatment 
for the second fraction was done based on the ap-
proved plan of the first fraction. Before the scan, 
10 mL of diluted Contrast in NS (Normal Saline) 
is instilled in the bladder as a routine protocol. No 
intravenous contrast is given as a routine proce-
dure. To minimize patient movement during CT 
scans, every attempt was made to keep the applica-
tor in position and to complete the entire proce-
dure within the shortest possible time. The scan was 
taken with 3 mm slice thickness through the pelvis, 
from the highest point of the iliac crest to the up-
per thigh using a 16 slice CT simulator (Brilliance 
Big Bore, Philips, Amsterdam, Netherlands); all CT 
slices were transferred to the treatment planning 
computer. Contouring of the organs at risk, OARS 
(bladder, rectum, and sigmoid colon) was done 
on axial sections as solid organs. The treatment 
planning was done using Varian Treatment Plan-
ning System (Eclipse version 13.5, Varian Medical 
Systems, Palo Alto, California). The planning was 
done using a uniform loading pattern with dose 
prescriptions to point A only. The plan was further 
optimized by dose point optimization to keep the 
bladder, rectum and sigmoid D2cc doses limited 
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to 85 Gy3 equivalent dose in 2 Gy fraction (EQD2) 
70 Gy3 EQD2 and 70 Gy3 EQD2, respectively. Dose 
prescription to HR-CTV was not done. 
study technique and data collection
Brachytherapy plans were accessed in the Treat-
ment Planning Computer; HR-CTV contouring 
was done following Viswanathan et al. guidelines 
with the help of available pre-brachytherapy MR 
images [17]. The presence of any post-EBRT vi-
able disease in the parametrium led to exclusion of 
cases. Contouring was rechecked by another senior 
radiation oncologist, and with any discordance by 
more than 10%, the volume was redrawn. The vol-
ume of HR-CTV, bladder, and rectum was collected 
from dose statistics. HR-CTV D90, D98, rectal dose 
(2cc, 1cc, 0.1cc), bladder dose (2cc, 1cc, 0.1cc), sig-
moid dose (2cc) was collected from DVH (Dose 
Volume Histogram). Dimensions of HR-CTV were 
recorded from appropriate sagittal, coronal, and 
axial sections. Follow up information was evalu-
ated from records, data on disease recurrence was 
noted. The recurrence was detected clinically and 
confirmed either by MRI/PET — positron emis-
sion tomography computed tomography (PET-CT) 
or wherever possible, by biopsy. Local recurrence 
was defined as any clinical and/or radiological evi-
dence of disease in the pelvis in patients achieving 
complete response clinically after completion of 
brachytherapy.
Definitions 
HR-CTV — high-risk clinical target volume. It is 
the volume bearing the highest risk for recurrence 
and is selected by clinical examination and imaging 
at the time of brachytherapy (ICRU 89);
HR-CTV D90 — it is the minimum dose received 
by 90% of the volume of the HR-CTV;
HR-CTV D98 — it is the minimum dose received 
by 98% of the volume of the HR-CTV (near mini-
mum target dose);
D2cc — minimum dose received by maximally ir-
radiated 2cc volume (OAR).
analysis of data
The statistical analysis was done using IBM SPSS 
(Statistical Package for the Social Sciences) 20 soft-
ware. Descriptive statistics were used to report pa-
tient characteristics and dose-volume characteris-
tics of HR-CTV and OARs. Comparison of mean 
Point A and HR-CTV D90 and D98 dose in patients 
with disease recurrence and locoregionally con-
trolled disease was done using Independent Sam-
ples T-test with a significance level of 0.05. Fisher’s 
exact test was used to compare local recurrence in 
terms of HR-CTV D90 dose. Kaplan Meier time to 
event analysis was used to assess progression-free 
survival (PFS). The time to progression was taken 
from completion of brachytherapy to any evidence 
of local progression/recurrence. 
results
48 patients were taken for the study; all had his-
tologically proven Squamous Cell Carcinoma. The 
median age was 48 years. 13 patients (27.1%) were 
in the pre-menopausal age group, the rest were 
post-menopausal. 32 patients (66.67%) were Inter-
national Federation of Gynecology and Obstetrics 
(FIGO) Stage IIB, the rest were at FIGO Stage IIA 
[19]. 45.83% of patients had received at least 4 cy-
cles of concurrent cisplatin 40 mg/m2 BSA (Tab. 1).
The dose-volume parameters are reported in 
Table 2. Mean point A EQD2 dose was 77.62 ± 2.10 
Gy10. Mean HR-CTV volume was 28 ± 5.03 cc and 
mean HR-CTV D90 and D98 EQD2 dose was 
82.46 ± 6.58 Gy10 and 69.29 ± 3.96, respectively. The 
rectal volume, bladder volume, and their respective 
D2cc, D1cc, and D0.1cc EQD2 doses are mentioned 
in Table 2. Age, bladder volume, rectal volume, and 
HR-CTV volume were not significantly different 
between patients with recurrent and locoregionally 
table 1. patient characteristics
Patient characteristics
Median age
48 years  
(minimum — 35 years, 


















FIGO — International Federation of Gynecology and Obstetrics; cT — cisplatin
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controlled disease (p-value = 0.272, 0.767, 0.556 
and 0.575, respectively, all non-significant, from 
independent samples T-test).
A median follow up was 30 months with 36 
(75%) patients having locoregionally controlled dis-
ease and 12 (25%) developing local recurrence. The 
comparison of mean doses to Point A and HR-CTV 
in patients with local recurrence and locoregion-
ally controlled disease are reported in Table 3. The 
mean point A EQD2 dose in patients with local re-
currence of disease and loco-regionally controlled 
disease was 77.94 ± 2.49 Gy10 and 77.52 ± 1.99 
Gy10 respectively (non-significant, p-value 0.59 
from unpaired T-test). The mean HR-CTV D90 
EQD2 dose in patients with local recurrence and 
patients with loco-regionally controlled disease was 
77.96 ± 4.81 Gy10 and 83.97 ± 6.46 Gy10, respectively. 
Mean HR-CTV D90 EQD2 dose was significantly 
greater in patients with locoregionally controlled 
disease (p-value = 0.002, significant). Similarly, 
HR-CTV D98 EQD2 dose was significantly higher 
in patients with locoregionally controlled disease 
(p-value = 0.013).
The total prescription dose to point A was 79.75 
Gy10 (from 50 Gy EBRT and 3# of 7 Gy to point 
A ICBT). Thus, for comparison of clinical outcome, 
we divided the patients into two groups based on 
whether the HR-CTV receives the prescription 
dose (79.75 Gy10 EQD2) or not (Tab. 4). During 
the follow up period, the patients who received an 
HR-CTV D90 EQD2 dose of more than or equal 
to 79.75 Gy10 EQD2 had significantly higher lo-
coregional control than patients receiving less than 
79.75 Gy10 EQD2 ( 87.1% vs. 52.9%,p = 0.015, Fish-
er’s exact test).
Figure 2 represents Kaplan Meier plot for pro-
gression free survival based on HR-CTV D90 
EQD2 dose. 
Progression free survival was significantly better 
for patients receiving HR-CTV D90 EQD2 dose of 
79.75 GY10 or more (p-value = 0.007, log-rank test). 
The median PFS was not reached. Three-year pro-
gression free survival was 87.1% in patients receiv-
ing HR-CTV D90 EQD2 dose of 79.75Gy10 or more, 
while it was 52.9% in patients receiving HR-CTV 
D90 dose of less than 79.75 Gy10.
table 2. Dose volume characteristics
Mean ± SD





3.27 ± 0.27 cm
3.15 ± 0.52 cm
2.9 ± 1.8 cm
rectal volume 48.12 ± 19.73 cc
bladder volume 70.31 ± 16.83 cc




82.46 ± 6.58 Gy10





68.31 ± 5.75 Gy3
72.78 ± 7.01 Gy3





81.30 ± 10.34 Gy3
87.15 ± 10.32 Gy3
100.22 ± 12.39 Gy3
sigmoid D2cc EQD2 64.28 ± 2.68 Gy3
table 3. comparison of mean point a and hr-cTV doses in patients with disease recurrence and locoregionally controlled 
disease
Mean ± standard deviation [Gy10] p-value (independent samples 
t-test)Local Recurrence Loco regionally controlled
point a eQD2 77.94 ± 2.49 77. 52  ± 1.99 0.59
hr-cTV D90 eQD2 77.96  ± 4.81 83.97  ± 6.46 0.002
hr-cTV D98 eQD2 67.36  ± 3.82 69.94  ± 3.76 0.013
table 4. Locoregional control in patients based on hr-cTV 







Hr-ctV D90 EQD2 dose
Less than 79.75 Gy10
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Discussion
MRI based adaptive brachytherapy is the gold 
standard for intracavitary brachytherapy of carci-
noma cervix and recent recommendations are pro-
vided by Gyn GEC ESTRO [10, 11] working group 
and ICRU 89(9). The standard was set based on the 
results of various studies [21–23]. With the publica-
tion of results of RetroEMBRACE & other studies, 
improvement in target coverage and overall sur-
vival was shown with [15, 24, 25].
However, implementation of such recommen-
dations is not just limited to knowledge, training, 
and experience, it requires state of the art equip-
ment and applicators, much of which is not avail-
able at state-funded high volume centers. A prac-
tice pattern survey by the same author among 
young radiation oncologists in India found that 
only about 9% of centers use routine MRI based 
planning versus 50% using CT based planning 
[25]. This is perhaps because most centers have 
a CT simulator which is essential for EBRT plan-
ning, and hence the availability of CT based rec-
ommendation is very essential for brachytherapy 
planning in such centers. However, the use of 
CT as cervical brachytherapy imaging is limit-
ed by the poor anatomical delineation [17]. The 
GTV cannot be delineated on a CT scan, there 
is a limited visualization of parametrial disease, 
the upper end of the cervix cannot be differenti-
ated from the uterus, and the disease extension 
on the uterine cavity cannot be visualized. In this 
study we have selectively included the subgroups 
of patients without any residual parametrial dis-
Figure 1. Brachytherapy planning cT in various sections showing hr-cTV (red), bladder (blue), and rectum (yellow) 
contouring and isodose curves covering hr-cTV in various sections. A–c. hr-cTV contoured on cT scan in sagittal, coronal, 
and axial sections, respectively. c, D. 90% (green) and 100% (white) isodose curves covering the hr-cTV in coronal and 
sagittal sections. E. Dose color wash showing covering of hr-cTV with 90% isodose in the axial section
a B c
D e F
Figure 2. Kaplan-Meier plot for progression-free survival 
based on hr-cTV D90 eQD2 dose. Green curve represents 
patients receiving hr-cTV D90 dose ≥ 79.75 Gy10, blue curve 
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ease post EBRT or concurrent chemoradiotherapy, 
thus eliminating the contouring uncertainties of 
the parametrial disease. 
A study by Rahul Krishnatry et al. suggested 
that no significant dosimetric difference in terms 
of V100, D90, and D100 exists between CT and 
MR contouring, standardized guidelines were not 
dictated [21]. The requirement of CT guidelines has 
been addressed in various trials that have tried to 
establish a CT based guidelines for CTV contour-
ing in the cervix [17–19, 27]. The recommendations 
provided by JRSOG [26] used MRI scans at diagno-
sis and at brachytherapy to delineate cervical CTV. 
Those recommendations could not be taken in our 
study as the contouring was done retrospectively 
and MRI plates were not always available for refer-
ence. The CT standardized guidelines provided by 
Viswanathan et al. [18] did not require the use of 
MRI scans or contrast enhancement. The updated 
guidelines from the same author were adopted for 
our study [17].
The CT based HR-CTV contouring recommen-
dations lacked adequate clinical data on local con-
trol and survival. However, in the RetroEMBRACE, 
139/731 (19.1%) of patients were treated with CT 
based HR-CTV contouring, separate data on the 
clinical outcome of that particular subgroup was 
not available [15].
Although our study showed good locoregional 
control in the group where HR-CTV D90 received 
at least 79.75 Gy10 EQD2 (from table 4), there was 
more local failure in our study population, which is 
more than historical image-guided brachytherapy 
cohorts [15, 27–30]. A study by Mahanshetty et 
al. reported local control in 22/24 patients after 
a median follow up of 10 months [31]. A study by 
D Simpson et al. reported a 1-year locoregional 
failure of 2.2% [30]. Kusada et al. reported a 2-year 
local control of 83% [32]. Rijkmans et al. reported 
a 3-year overall survival and local control of 93% 
and 86% with the use of image-guided brachyther-
apy [29].
Our inferior local control could be due to several 
limitations in our study. Firstly, the study protocol 
was designed after completion of patients’ treat-
ment, so there was no protocol for quality control of 
EBRT and brachytherapy technique and our study 
relied on treatment decisions, dose prescription 
and optimization partially from institutional proto-
cols and partially from treating physician’s experi-
ence. Secondly, the HR-CTV contouring was done 
post-treatment, so dose prescription and optimiza-
tion was not based on HR-CTV so the recommend-
ed D90 dose of ≥ 85 GY10 could not be achieved 
in several patients. However, our aim was not to 
achieve good local control in the population which 
was not under the control of the study protocol, 
we wanted to show whether dose to the HR-CTV 
contoured on CT scan had any impact on local con-
trol. We managed to show a significantly good local 
control in patients who received the prescription 
dose to HR-CTV compared to those who did not. 
A comparative study from TMH, Mumbai, inferred 
that HR-CTV volumes can be contoured on CT as 
compared with MRI, provided there is documenta-
tion of disease at diagnosis by clinical drawings and 
MRI, and real-time acquisition of TRUS images at 
various levels in relation to the cervical canal dur-
ing the procedure [19]. However, since there is an 
overestimation of HR-CTV volumes on CT based 
contouring as compared to MRI based contouring, 
this could result in a lower HR-CTV D90 that cor-
relates to local control.
Though more validation is required with a pro-
spective protocol with quality control of EBRT 
and ICBT, dose prescription and optimization to 
HR-CTV and a longer follow up, this study merits 
in providing an indirect validation of using CT 
based HR-CTV contouring backed by providing 
clinical results of recurrence correlation with the 
mean D90 of the HR-CTV thus contoured. Incor-
poration of real-time ultrasonography may add to 
the validity and reliability of such CT based delin-
eation. However, since original dose prescription 
and optimization were not done to HR-CTV, there 
was no control on the toxicity profile of OAR based 
on HR-CTV dosimetry, hence no comment could 
be made on the same. 
conclusion
CT based HR-CTV volume delineation with the 
help of pre-brachytherapy clinical diagrams and 
MRI imaging may be feasible in a select subgroup of 
patients with complete or near-complete response 
to External Beam radiation. Prospective studies 
need to be undertaken to rationalize dose prescrip-
tion CT based HR-CTV as this would popularise 
image-based adaptive brachytherapy, especially in 
the resource constraint settings.







The authors would like to thank all staff and faculty 
the Department of Radiotherapy Medical College 
Kolkata, with special thanks to the physics team 
of Mr Jayanta Kumar Pal and his colleagues and 
the brachytherapy nurses team for rendering their 
support and cooperation in undertaking this study. 
references
1. srivastava aN, Misra Js, srivastava s, et al. cervical cancer 
screening in rural India: status & current concepts. In-
dian J Med res. 2018; 148(6): 687–696, doi: 10.4103/ijmr.
IJMr_5_17, indexed in pubmed: 30778002.
2. cho O, chun M. Management for locally advanced cervi-
cal cancer: new trends and controversial issues. radiat 
Oncol J. 2018; 36(4): 254–264, doi: 10.3857/roj.2018.00500, 
indexed in pubmed: 30630264.
3. Lanciano rM, Won M, coia Lr, et al. pretreatment and treat-
ment factors associated with improved outcome in squa-
mous cell carcinoma of the uterine cervix: a final report 
of the 1973 and 1978 patterns of care studies. Int J radiat 
Oncol Biol phys. 1991; 20(4): 667–676, doi: 10.1016/0360-
3016(91)90007-q, indexed in pubmed: 2004942.
4. chassagne D, Dutreix a, almond p, et al. report 38. J Int 
comm radiat Units Meas. 1985; 20(1): Np–Np.
5. srivastava a, Datta Nr. Brachytherapy in cancer cervix: 
Time to move ahead from point a? World J clin Oncol. 
2014; 5(4): 764–774, doi: 10.5306/wjco.v5.i4.764, indexed 
in pubmed: 25302176.
6. Datta Nr. From ‚points’ to ‚profiles’ in intracavitary brachy-
therapy of cervical cancer. curr Opin Obstet Gynecol. 
2005; 17(1): 35–41, doi: 10.1097/00001703-200502000-
00007, indexed in pubmed: 15711409.
7. Katz a, eifel pJ. Quantification of intracavitary brachy-
therapy parameters and correlation with outcome in 
patients with carcinoma of the cervix. Int J radiat Oncol 
Biol phys. 2000; 48(5): 1417–1425, doi: 10.1016/s0360-
3016(00)01364-x, indexed in pubmed: 11121642.
8. Viswanathan aN, erickson Ba. Three-dimensional imaging 
in gynecologic brachytherapy: a survey of the american 
Brachytherapy society. Int J radiat Oncol Biol phys. 2010; 
76(1): 104–109, doi: 10.1016/j.ijrobp.2009.01.043, indexed 
in pubmed: 19619956.
9. International commission on radiation Units and Meas-
urements (IcrU) [Internet]. https://icru.org/content/
reports/prescribing-recording-and-reporting-brachyther-
apy-for-cancer-of-the-cervix-report-no-89 (2019 Dec 23).
10. haie-Meder c, pötter r, Van Limbergen e, et al. Gynaeco-
logical (GYN) Gec-esTrO Working Group. recommenda-
tions from Gynaecological (GYN) Gec-esTrO Working 
Group (I): concepts and terms in 3D image based 3D 
treatment planning in cervix cancer brachytherapy 
with emphasis on MrI assessment of GTV and cTV. 
radiother Oncol. 2005; 74(3): 235–245, doi: 10.1016/j.
radonc.2004.12.015, indexed in pubmed: 15763303.
11. pötter r, haie-Meder c, Van Li, et al. recommendations 
from gynaecological (GYN) Gec esTrO working group 
(II): concepts and terms in 3D image-based treatment 
planning in cervix cancer brachytherapy-3D dose volume 
parameters and aspects of 3D image-based anatomy, 
radiation physics, radiobiology. radiother Oncol. 2006; 
78(1): 67–77, doi: 10.1016/j.radonc.2005.11.014, indexed 
in pubmed: 16403584.
12. Nag s, cardenes h, chang s, et al. Image-Guided 
Brachytherapy Working Group. proposed guidelines for 
image-based intracavitary brachytherapy for cervical 
carcinoma: report from Image-Guided Brachytherapy 
Working Group. Int J radiat Oncol Biol phys. 2004; 60(4): 
1160–1172, doi: 10.1016/j.ijrobp.2004.04.032, indexed in 
pubmed: 15519788.
13. hellebust Tp, Kirisits c, Berger D, et al. Gynaecological 
(GYN) Gec-esTrO Working Group. recommendations 
from Gynaecological (GYN) Gec-esTrO Working Group: 
considerations and pitfalls in commissioning and ap-
plicator reconstruction in 3D image-based treatment 
planning of cervix cancer brachytherapy. radiother Oncol. 
2010; 96(2): 153–160, doi: 10.1016/j.radonc.2010.06.004, 
indexed in pubmed: 20663578.
14. Dimopoulos Jca, petrow p, Tanderup K, et al. recommen-
dations from Gynaecological (GYN) Gec-esTrO Working 
Group (IV): Basic principles and parameters for Mr im-
aging within the frame of image based adaptive cervix 
cancer brachytherapy. radiother Oncol. 2012; 103(1): 
113–122, doi: 10.1016/j.radonc.2011.12.024, indexed in 
pubmed: 22296748.
15. sturdza a, pötter r, Fokdal LU, et al. Image guided 
brachytherapy in locally advanced cervical cancer: Im-
proved pelvic control and survival in retroeMBrace, a 
multicenter cohort study. radiother Oncol. 2016; 120(3): 
428–433, doi: 10.1016/j.radonc.2016.03.011, indexed in 
pubmed: 27134181.
16. Nomden cN, pötter r, de Leeuw aac, et al. eMBrace 
collaborative Group. Nodal failure after chemo-radiation 
and MrI guided brachytherapy in cervical cancer: patterns 
of failure in the eMBrace study cohort. radiother Oncol. 
2019; 134: 185–190, doi: 10.1016/j.radonc.2019.02.007, 
indexed in pubmed: 31005214.
17. Viswanathan aN, erickson B, Gaffney DK, et al. comparison 
and consensus guidelines for delineation of clinical target 
volume for cT- and Mr-based brachytherapy in locally 
advanced cervical cancer. Int J radiat Oncol Biol phys. 
2014; 90(2): 320–328, doi: 10.1016/j.ijrobp.2014.06.005, 
indexed in pubmed: 25304792.
18. Viswanathan aN, Dimopoulos J, Kirisits c, et al. computed 
tomography versus magnetic resonance imaging-based 
contouring in cervical cancer brachytherapy: results of a 
prospective trial and preliminary guidelines for standard-
ized contours. Int J radiat Oncol Biol phys. 2007; 68(2): 
491–498, doi: 10.1016/j.ijrobp.2006.12.021, indexed in 
pubmed: 17331668.
19. Murakami N, Kasamatsu T, Wakita a, et al. cT based three 
dimensional dose-volume evaluations for high-dose 
rate intracavitary brachytherapy for cervical cancer. BMc 
cancer. 2014; 14: 447, doi: 10.1186/1471-2407-14-447, 
indexed in pubmed: 24938757.
Reports of Practical Oncology and Radiotherapy 2021, vol. 26, no. 2
https://journals.viamedica.pl/rpor178
20. Bhatla N, Berek Js, cuello Fredes M, et al. revised FIGO 
staging for carcinoma of the cervix uteri. Int J Gynaecol 
Obstet. 2019; 145(1): 129–135, doi: 10.1002/ijgo.12749, 
indexed in pubmed: 30656645.
21. Wachter-Gerstner N, Wachter s, reinstadler e, et al. The 
impact of sectional imaging on dose escalation in endo-
cavitary hDr-brachytherapy of cervical cancer: results of 
a prospective comparative trial. radiother Oncol. 2003; 
68(1): 51–59, doi: 10.1016/s0167-8140(03)00083-5, in-
dexed in pubmed: 12885452.
22. cT or MrI for Image-based Brachytherapy in cervi-
cal cancer. https://www.researchgate.net/publica-
tion/221846219_cT_or_MrI_for_Image-based_Brachy-
therapy_in_cervical_cancer (2020 Jan 2).
23. Dimopoulos Jca, schard G, Berger D, et al. systematic eval-
uation of MrI findings in different stages of treatment of 
cervical cancer: potential of MrI on delineation of target, 
pathoanatomic structures, and organs at risk. Int J radiat 
Oncol Biol phys. 2006; 64(5): 1380–1388, doi: 10.1016/j.
ijrobp.2005.10.017, indexed in pubmed: 16580496.
24. serban M, Kirisits c, pötter r, et al. eMBrace collabora-
tive Group. Isodose surface volumes in cervix cancer 
brachytherapy: change of practice from standard 
(point a) to individualized image guided adaptive (eM-
Brace I) brachytherapy. radiother Oncol. 2018; 129(3): 
567–574, doi: 10.1016/j.radonc.2018.09.002, indexed in 
pubmed: 30243671.
25. pötter r, Georg p, Dimopoulos Jca, et al. clinical out-
come of protocol based image (MrI) guided adaptive 
brachytherapy combined with 3D conformal radiotherapy 
with or without chemotherapy in patients with locally 
advanced cervical cancer. radiother Oncol. 2011; 100(1): 
116–123, doi: 10.1016/j.radonc.2011.07.012, indexed in 
pubmed: 21821305.
26. Bandyopadhyay a, Basu p, roy K, et al. Treatment of locally 
advanced carcinoma cervix with special emphasis on 
brachytherapy: a practice pattern survey among young 
radiation oncologist of India. south asian J cancer. 2018; 
7(4): 231–235, doi: 10.4103/sajc.sajc_198_17, indexed in 
pubmed: 30430090.
27. Ohno T, Wakatsuki M, Toita T, et al. The Working Group 
of the Gynecological Tumor committee of the Japanese 
radiation Oncology study Group (JrOsG). recommen-
dations for high-risk clinical target volume definition 
with computed tomography for three-dimensional 
image-guided brachytherapy in cervical cancer patients. 
J radiat res. 2017; 58(3): 341–350, doi: 10.1093/jrr/rrw109, 
indexed in pubmed: 27837120.
28. Kawashima a, Isohashi F, Mabuchi s, et al. a 3-year follow-
up study of radiotherapy using computed tomography-
based image-guided brachytherapy for cervical cancer. J 
radiat res. 2019; 60(2): 264–269, doi: 10.1093/jrr/rry104, 
indexed in pubmed: 30649485.
29. rijkmans ec, Nout ra, rutten Ih, et al. Improved survival of 
patients with cervical cancer treated with image-guided 
brachytherapy compared with conventional brachyther-
apy. Gynecol Oncol. 2014; 135(2): 231–238, doi: 10.1016/j.
ygyno.2014.08.027, indexed in pubmed: 25172763.
30. simpson D, Yashar cM, Kannan N, et al. cT and MrI-based 
Image Guided Brachytherapy for cervical cancer: a Multi-
institutional report. Int J radiat Oncol Biol phys. 2012; 
84(3): s19, doi: 10.1016/j.ijrobp.2012.07.053.
31. MrI-guided high-dose-rate intracavitary brachytherapy in 
cervical cancers at Tata Memorial hospital: The initial clini-
cal outcome — Brachytherapy. https://www.brachyjour-
nal.com/article/s1538-4721(09)00030-0/abstract (2020 
Jul 9).
32. Kusada T, Toita T, ariga T, et al. computed tomography-
based image-guided brachytherapy for cervical cancer: 
correlations between dose-volume parameters and 
clinical outcomes. J radiat res. 2018; 59(1): 67–76, 
doi: 10.1093/jrr/rrx065, indexed in pubmed: 29186565.
